Bristol Myers Squibb (BMS), a leading global biopharmaceutical firm, has launched Mosaic, an innovative AI-driven content hub, signaling a new chapter in technology-enhanced patient care.

In collaboration with global professional services company Accenture, the new hub represents a significant advancement in AI-powered pharmaceutical commercialization.

Situated in Mumbai, Mosaic is a comprehensive, generative AI-driven platform designed to enhance BMS’s digital capabilities by pinpointing physicians’ educational requirements instantly and swiftly generating patient-focused content on a large scale. The initiative highlights BMS’s goal to spearhead the upcoming stage of technology-driven healthcare interaction.

Adam Lenkowsky, Chief Commercialization Officer of Bristol Myers Squibb, and Ndidi Oteh, Global CEO of Accenture Song, officially launched the Mosaic content hub.

The future of healthcare involves engaging clinicians and patients in their own environments and doing it in impactful manners. “This collaboration showcases our BMS strategy for comprehensive digital transformation,” stated Adam Lenkowsky, Chief Commercialization Officer at Bristol Myers Squibb.

The Mosaic content hub will enhance patient experience by enabling our marketing teams to develop and distribute relevant, timely communications with healthcare professionals more efficiently.

India is vital to Bristol Myers Squibb’s international strategy. The firm has sustained its business activities in the nation for over twenty years, providing pharmaceuticals in oncology, hematology, and cardiology.

BMS has recently broadened its presence by launching a cutting-edge facility in Hyderabad, hiring over 3,000 professionals in Business Insights and Technology, Global Drug Development, Global Product Development and Supply, and Enabling Functions.

BMS is allocating $130 million to enhance a wide array of AI projects in marketing and commercialization, with Mosaic being a significant part of that investment. Utilizing India's extensive digital knowledge and cooperative environment, the company intends to expand next-generation, AI-based solutions throughout its worldwide operations.

The science-driven, patient-focused mission of Bristol Myers Squibb is being increasingly accelerated by developments in artificial intelligence and machine learning.

“We are strategically utilizing and incorporating AI technologies throughout BMS to enhance efficiency, facilitate data access, increase productivity, and improve decision-making – all aimed at assisting our global team in redefining our industry,” stated Anvita Karara, Vice President, Worldwide Commercialization Excellence.

Also Read: Semicon India 2025: Designing A Self-Reliant Semiconductor Hub

The Mosaic launch further strengthens a longstanding partnership between BMS and Accenture, collaborators for over 25 years. What started as a conventional services partnership has progressed into a strong collaboration centered on innovation, digital transformation, and operational excellence.

Also Read: The Global Fintech Fest 2025: Enabling Finance for Better World

The content hub located in Mumbai will assemble a sizable, diverse group of creatives and technologists to transform the development and delivery of marketing content on a large scale.

Also Read: 5 AI Initiatives by the Indian Government Driving National Growth

"Accenture and Bristol Myers Squibb are at the forefront of an AI-driven transformation in biopharma, using cutting-edge technologies to create significant results for patients. Mosaic exemplifies Bristol Myers Squibb's role in transforming the industry and establishing a new benchmark for hyper-personalized experiences for healthcare providers,” Oteh mentioned.